All In Biotech

Drug Trial Radar · NCT04143711

Study of DF1001 in Patients With Advanced Solid Tumors

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

270

Actual

Start

Nov 11, 2019

Primary completion

Dec 5, 2025

Study completion Dec 5, 2025

Sponsor

Lead sponsor
Dragonfly TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having either HER2 activated non-small cell lung cancer, hormone receptor (HR) positive HER2 negative metastatic breast cancer, or HER2 positive metastatic breast cancer. DF1001-001 will be administered as monotherapy or in combination; combinations are DF1001 + nivolumab, DF1001 + Nab paclitaxel, and DF1001 + sacituzumab govitecan-hziy.

Conditions

  • Solid Tumor, Adult

Interventions

  • DF1001Drug

    Immunotherapy agent targeting NK cells.

  • NivolumabDrug

    Anti-PD-1 immunotherapy agent

  • Nab paclitaxelDrug

    A chemotherapy treatment combining paclitaxel with albumin

  • Sacituzumab Govitecan-hziyDrug

    A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of number of dose limiting toxicities experienced on study as defined per criteria in the study protocolTime frame: First 3 weeks of treatment for each subject.
  2. Assess Overall Response RateTime frame: Through 90 days after completion of the study, an average of 1 year.
  3. Assess number of adverse events observed during treatment with DF1001 in combination with NivolumabTime frame: Screening visit up to 28 days after last treatment on study.
  4. Assess number of adverse events observed during treatment with DF1001 in combination with Nab paclitaxelTime frame: Screening visit up to 28 days after last treatment on study.
  5. Assess number of adverse events observed during treatment with DF1001 in combination with Sacituzumab govitecan-hziyTime frame: Screening visit up to 28 days after last treatment on study.

Locations

44 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California Irvine Medical Center

    Irvine, California

  • University of Southern California

    Los Angeles, California

  • Sharp Healthcare

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • University of Kansas Medical Center Research Institute, Inc.

    Westwood, Kansas

  • Louisiana State University

    New Orleans, Louisiana

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center

    New York, New York

  • Montefiore Einstein Center for Cancer Care

    The Bronx, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Rhode Island Hospital

    Providence, Rhode Island

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Multicare Health System Tacoma General Hospital

    Tacoma, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Centre Hospitalier de l'Ardenne

    Arlon, Belgium

  • Grand Hopital de Charleroi

    Charleroi, Belgium

  • Domaine Universitaire du Sart Tilman; CHU de Liege

    Liège, Belgium

  • Herlev og Gentofte Hospital

    Herlev, Denmark

  • Rigshospitalet

    Copenhagen, Capital Region, Denmark

  • Groupe Hospitalier Saint Andre

    Bordeaux, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Leon Berard

    Lyon, France

  • Institut Paoli Calmettes

    Marseille, France

  • Institut Regional du Cancer de Montepelier

    Montpellier, France

  • ICO - Site Rene Gauducheau

    Saint-Herblain, France

  • Institut Claudius Regaud

    Toulouse, France

  • Institut Curie

    Paris, Paris, France

  • Amsterdam University Medical Center

    Amsterdam, Netherlands

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands

  • Maasticht University Medical Center

    Maastricht, Netherlands

  • Radboud University Nijmegen

    Nijmegen, Netherlands

  • Erasmus University Medical Center

    Rotterdam, Netherlands

  • UMC Utrecht

    Utrecht, Netherlands

  • Inje University Haeundae Paik Hospital

    Busan, South Korea

  • National Cancer Center

    Goyang-si, South Korea

  • Ajou University Hospital

    Gyeonggi-do, South Korea

  • CHA Bundang Medical Center, CHA University

    Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.